Cognizant, Gilead seal $800 million deal for digital transformation
NEW JERSEY, UNITED STATES — Professional services firm Cognizant has sealed a deal valued at $800 million over the next five years with Gilead Sciences, a leading biopharmaceutical company.
This expanded partnership will entrust Cognizant with the task of managing and modernizing Gilead’s global IT landscape, which includes infrastructure, applications, platforms, and advanced analytics, accelerating its digital transition.
This strategic alliance aims to streamline Gilead’s operations, allowing quicker market launch for their life-saving medicines aimed at treating conditions like HIV, viral hepatitis, and cancer.
Marc Berson, Gilead’s Senior Vice President and CIO, praised Cognizant’s expertise for contributing to their digital journey while ensuring steady and secure operations that further advance their research and commercialization efforts.
Cognizant’s extended role will also involve boosting Gilead’s transition to cloud computing, implementing Generative AI and AI automation to digitally revamp their operations, and improve both internal and external client interactions.
California-based Gilead operates in over 35 countries, developing pioneering medicines for severe illnesses. Cognizant, a $19 billion global technology and digital services provider with over 350,000 employees, ranks fifth in the Time Doctor OA500, an index of the world’s top 500 outsourcing firms.
